Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.

Terry L. Ng,Megan M. Tu,Mohammed Fk Ibrahim,Bassam Basulaiman,Sharon F. McGee,Amirrtha Srikanthan,Ricardo Fernandes,Lisa Vandermeer,Carol Stober,Marta Sienkiewicz,Ahwon Jeong,Deanna Saunders,Arif Awan,Brian Hutton,Mark Clemons

Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.

2020

Terry L. Ng
Megan M. Tu
Mohammed Fk Ibrahim
Bassam Basulaiman
Sharon F. McGee
Amirrtha Srikanthan
Ricardo Fernandes
Lisa Vandermeer
Carol Stober
Marta Sienkiewicz
Ahwon Jeong
Deanna Saunders
Arif Awan
Brian Hutton
Mark Clemons

e24083Background: Randomized clinical trials evaluated bone modifying agents (BMAs) such as bisphosphonates and denosumab for bone metastases for 1-2 years in duration even though BMA therapy is co...

Keywords:

Castrate-resistant prostate cancer
Oncology
Toxicity
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations